Citation tools
"Radioligand therapy using combination of Ac-225 and Lu-177 labelled PSMA ligands for progressive end-stage metastatic prostate cancer: effective trade-off between response and toxicity ." Journal of Nuclear Medicine
60.supplement 1
(2019):
464.
Web. 19 April. 2024.